Imara initiates Phase I clinical study of IMR-687 to treat sickle-cell disease

US-based biotechnology company Imara has initiated its Phase I clinical study of IMR-687 to treat patients with sickle-cell disease and other haemoglobinopathies.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news